Scarica l'app Stockscreener
8.155
0.31%
0.025
Zevra Therapeutics Inc Borsa (ZVRA) Ultime notizie
Zevra Therapeutics (NASDAQ:ZVRA) Upgraded by Cantor Fitzgerald to "Strong-Buy" Rating - MarketBeat
Janney Montgomery Scott LLC Has $2.48 Million Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Cantor Fitzgerald Upgrades Zevra Therapeutics (NASDAQ:ZVRA) to “Strong-Buy” - Defense World
Zevra Therapeutics to Present at the 21st Annual WORLDSymposium™ - GlobeNewswire
Breakthrough Treatment for Rare Brain Disease: Zevra's MIPLYFFA Earns Major Industry Recognition - StockTitan
Zevra Therapeutics to Participate at Upcoming Investor Conferences - The Manila Times
Rare Disease Leader Zevra Takes Center Stage at Major Healthcare Investment Events - StockTitan
Cantor Fitzgerald Predicts ZVRA FY2025 Earnings - MarketBeat
Cantor Fitzgerald Weighs in on ZVRA FY2025 Earnings - MarketBeat
Objective long/short (ZVRA) Report - Stock Traders Daily
Brokerages Set Zevra Therapeutics, Inc. (NASDAQ:ZVRA) PT at $21.57 - MarketBeat
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of “Buy” by Analysts - Defense World
Barclays PLC Buys 42,926 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat
Barclays PLC Has $399,000 Stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Positive Signs As Multiple Insiders Buy Zevra Therapeutics Stock - Yahoo Finance
Cantor Fitzgerald Weighs in on ZVRA FY2024 Earnings - Defense World
Learn to Evaluate (ZVRA) using the Charts - Stock Traders Daily
FY2024 EPS Forecast for Zevra Therapeutics Raised by Analyst - MarketBeat
Zevra Therapeutics (NASDAQ:ZVRA) Coverage Initiated at Cantor Fitzgerald - Defense World
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Bought by Barclays PLC - Defense World
Geode Capital Management LLC Has $7.25 Million Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat
Geode Capital Management LLC Boosts Stock Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
(ZVRA) Technical Pivots with Risk Controls - Stock Traders Daily
Sanctuary Advisors LLC Trims Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat
Sanctuary Advisors LLC Has $194,000 Stock Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
State Street Corp Has $5.36 Million Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Analysts Expect Breakeven For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Before Long - Yahoo Finance
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Analysts Set Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Target Price at $21.00 - MarketBeat
13,551 Shares in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Bought by XTX Topco Ltd - Defense World
(ZVRA) Investment Analysis and Advice - Stock Traders Daily
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Position Increased by Charles Schwab Investment Management Inc. - Defense World
Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024 - The Manila Times
Zevra Therapeutics Secures Coveted Spot in Nasdaq Biotechnology Index Following Transformative Year - StockTitan
Zevra Therapeutics' SWOT analysis: rare disease drug maker's stock poised for growth - Investing.com
Fmr LLC Acquires 2,312,384 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat
Zevra Therapeutics Restructures to Focus on Rare Diseases - MSN
A drug for fewer than 1,000 patients? Awareness and diagnosis are key. - PharmaVoice
Zevra Therapeutics Announces Organizational Changes - The Manila Times
Zevra Therapeutics, Inc. Announces Departure of Executives - Marketscreener.com
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has caught the attention of institutional investors who hold a sizeable 42% stake - Yahoo Finance
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives $21.00 Consensus Price Target from Brokerages - MarketBeat
Vestal Point Capital LP Purchases Shares of 525,000 Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat
179,874 Shares in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Purchased by Propel Bio Management LLC - MarketBeat
Zevra Therapeutics CEO to Present at Major Healthcare Investment Conferences | ZVRA Stock News - StockTitan
Zevra Therapeutics (NASDAQ:ZVRA) Reaches New 52-Week HighShould You Buy? - MarketBeat
0.43%
3.18%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):